Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 17/20 | 0.64 |
| ▸ | MC3R | P41968 | 7/20 | 0.62 |
| ▸ | MC5R | P33032 | 7/20 | 0.62 |
| ▸ | MC1R | Q01726 | 7/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.62 |
| ▸ | PRCP | P42785 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3170759 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL71984 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29904550 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL15252713 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL91103 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL70497 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL30593923 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL1920391 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL4939210 | 0.99 | MC4R (0.63) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL4939214 | 0.99 | MC4R (0.63) | MC4RMC3RMC5RMC1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116888110-A | Melanocortin-4 receptor agonists | 株式会社LG 化学 | 2023-10-13 | — | — | CN | disclosed |
| US-8569299-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2350060-B1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130143859-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2579716-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8129413-B2 | Crystalline forms of MC4R agonist and process for synthesis | MERCK SHARP & DOHME CORP. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129413-B2 | Crystalline forms of MC4R agonist and process for synthesis | MERCK SHARP & DOHME CORP. (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2011156220-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-1610789-B1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2010-07-21 | — | — | EP | disclosed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1648457-A2 | PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006020277-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1613601-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co. Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1383501-A4 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2005077935-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LIMITED (GB) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| WO-2005009950-A2 | PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004089307-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO. INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1383501-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002068388-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176772-A1 | Pharmaceutically active compounds | MC4R, MC3R, MC5R | MC4R 1/4885MC3R 2/4885MC5R 3/4885 |
| US-20130143859-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PREP, PRCP, DPEP1 | MC4R 1101/4885MC3R 2867/4885MC5R 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.